| Literature DB >> 31222885 |
Marielle E Yohe1, Christine M Heske1, Elizabeth Stewart2, Peter C Adamson3, Nabil Ahmed4, Cristina R Antonescu5, Eleanor Chen6, Natalie Collins7, Alan Ehrlich8, Rene L Galindo9, Berkley E Gryder1, Heidi Hahn10, Sharon Hammond11, Mark E Hatley2, Douglas S Hawkins12, Madeline N Hayes13, Andrea Hayes-Jordan14, Lee J Helman15, Simone Hettmer16, Myron S Ignatius17, Charles Keller18, Javed Khan1, David G Kirsch19, Corinne M Linardic19, Philip J Lupo4, Rossella Rota20, Jack F Shern1, Janet Shipley21, Sivasish Sindiri1, Stephen J Tapscott22, Christopher R Vakoc23, Leonard H Wexler5, David M Langenau13.
Abstract
Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.Entities:
Keywords: cancer biology; early-phase clinical trials; genomics; rhabdomyosarcoma
Mesh：
Year: 2019 PMID： 31222885 PMCID： PMC6707829 DOI： 10.1002/pbc.27869
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167